RNA in cancer immunotherapy: unlocking the potential of the immune system

Research output: Contribution to journalArticlepeer-review


Recent advances in the manufacturing, modification, purification and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.

Original languageEnglish
Pages (from-to)3929-3939
Number of pages11
JournalClinical Cancer Research
Issue number18
Early online date2022
Publication statusPublished - 15 Sep 2022

Bibliographical note

©2022 The Authors; Published by the American Association for Cancer Research.


  • RNA
  • cancer
  • Immunotherapy
  • immune system


Dive into the research topics of 'RNA in cancer immunotherapy: unlocking the potential of the immune system'. Together they form a unique fingerprint.

Cite this